# 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

> **NCT03564197** · NA · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 80 (actual)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **OTHER:** 18F-PD-L1

## Key facts

- **NCT ID:** NCT03564197
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2025-01-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564197, "18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT03564197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*